TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today that it has begun the planning for a proof of concept human trial for breast cancer therapy in 2009 for CGEN-50001, a known central nervous system (“CNS”) drug. In recently completed in vitro and in vivo validation studies, co-administration of CGEN-50001 was shown to significantly increase the effect of Tamoxifen, a frequently used drug for the treatment of estrogen receptor (ER) positive breast cancer. This previously unknown action of CGEN-5001 was initially predicted in silico by Compugen’s New Indications Discovery Platform. Compugen has filed a patent for this usage.
